Paclitaxel-induced neuropathic pain is age dependent and devolves on glial response

Area of Science:

• Neuroscience
• Pharmacology
• Oncology

Background:

• Paclitaxel is a vital chemotherapy drug for refractory cancers.
• Peripheral neuropathic pain is a significant side effect of paclitaxel.
• This study investigates paclitaxel-induced neuropathy and spinal cord inflammation across different age groups in mice.

Purpose of the Study:

• To evaluate the severity of paclitaxel-induced neuropathy in young, adult, and aged mice.
• To assess the associated inflammatory response in the dorsal horn of the spinal cord.
• To determine the influence of age on paclitaxel's neurotoxic effects.

Main Methods:

• Assessed hyperalgesia using the plantar test and allodynia using the von Frey filament model.
• Quantified spinal cord microglia and astrocyte activation via Iba1 and glial fibrillary acidic protein immunofluorescence.
• Compared neuropathy and glial responses across young, adult, and aged male CD1 mice.

Main Results:

• Paclitaxel treatment induced hyperalgesia and allodynia in all mouse age groups.
• Neuropathy signs were most pronounced in young mice, followed by aged mice.
• Young and aged mice exhibited greater microglial and astrocytic activation in the spinal cord compared to adult mice, correlating with neuropathy severity.

Conclusions:

• Paclitaxel-induced neuropathy in mice is significantly influenced by age.
• The severity of neuropathy is directly related to the glial response in the spinal cord.
• Age is a critical factor in the manifestation and intensity of paclitaxel neurotoxicity.